Antitumoral effects of glycoconjugates on primary cultures of human pancreatic cancer cells obtained by echoendoscopy

MOLEJÓN, MI; WEIZ G; TELLECHEA JI; BRECCIA J; VACCARO, MI; VACCARO MI

Acta Gastroenterólogica Latinoamericana

Sociedad Argentina de Gastroenterología

Año: 2019

2469-1119

Pancreatic ductal adenocarcinoma (PDAC), which consti- tutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. PDAC belongs to one of the most chemo resistant cancers, in part due to its molec- ular and genetics features. Currently, available therapeutic options are surgery, radiation, chemotherapy, and immu- notherapy. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms. Our aim was to evaluate the antitumoral effect as a second line therapy, of enzymatically glycosylated compounds, hydroqui- none-rutinoside, on primary pancreatic tumoral cells. We found that glycoconjugates combined with antitumor agents,such as gemcitabine, improved single-treatment effects. These findings suggest that emerging trends towards glycoconjugates could be a promising approach for cancer therapies.